Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1242-1247

  Sester, M ^a   Giehl, C ^b   McNerney, R ^c   Kampmann, B ^d   Walzl, G ^e   Cuchi P ^f   Wingfield, C ^g   Lange, C ^h   Migliori, G B ⁱ   Kritski, A L ^j   Meyerhans, A ^k  

^a SAARLAND UNIVERSITY   (Germany)

^b European Research and Project Office GmbH   (Germany)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f UNAIDS   (Switzerland)

^g Treatment Action Group   (United States)

^h RESEARCH CENTER BORSTEL   (Germany)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^k UNIVERSITAT POMPEU FABRA   (Spain)

more..

Author keywords

Co infection; Drug resistance; Europe; HIV; Immunology; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; DISEASE TRANSMISSION; EUROPEAN UNION; FUNDING; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION CONTROL; INFECTION PREVENTION; LOWEST INCOME GROUP; MIXED INFECTION; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINATION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COMORBIDITY; CONGRESSES AS TOPIC; EUROPE; FEMALE; GROUP PROCESSES; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 78649728341     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00040910     Document Type: Review

References (35)

1. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523.
2. World Health Organization. Global Tuberculosis Control: A Short Update to the 2009 Report. www.who.int/tb/publications/global-report/2009/update/en/ index.html Date last accessed: September 13, 2010. Date last updated: March 2009.
3. UNAIDS. 2008 Report on the Global AIDS Epidemic. www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp Date last accessed: July 2008. Date last updated: August 2008.
4. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
5. World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing. www.who.int/tb/publications/global-report/2008/en/ Date last accessed: September 13, 2010. Date last updated: 2008.
6. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
7. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
8. World Health Organization. Treating 3 million by 2005. Making it Happen. The WHO Strategy. Geneva, World Health Organization, 2003.
9. World Health Organization. HIV/AIDS Programme: Towards Universal Access 2010. Geneva, World Health Organization, 2006.
10. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367: 952-955.
11. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
12. World Health Organization. The Global Plan to Stop TB 2006-2015. Geneva, World Health Organization, 2006.
13. World Health Organization. Interim Policy on Collaborative TB/HIV Activities. Geneva, World Health Organization, 2004.
14. ACTION 2009: Living with HIV, Dying of TB: A Critique of the Response of Global AIDS Donors to the Co-epidemic. Washington, RESULTS Educational Fund, 2009.
15. WHO, UNAIDS, PEPFAR. A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities - 2009 Revision. Geneva, World Health Organization, 2009.
16. Perumal R, Padayatchi N, Stiefvater E. The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. BMC Public Health 2009; 9: 243.
17. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-289.
18. Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320: 760-764.
19. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med 2007; 356: 2073-2081.
20. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455: 613-619.
21. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417: 95-98.
22. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-1180.
23. Hesseling AC, Cotton MF, Fordham von Reyn C, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12: 1376-1379.
24. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
25. Clancy L, Rieder HL, Enarson DA, et al. Tuberculosis elimination in the countries of Europe and other industrialized countries. Eur Respir J 1991; 4: 1288-1295.
26. Lengauer T, Sing T. Bioinformatics-assisted anti-HIV therapy. Nat Rev Microbiol 2006; 4: 790-797.
27. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-354.
28. De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol 2009; 19: 287-299.
29. Chou L, Harrington M, Huff B, et al. TAG 2009 pipeline report. New York, TAG, 2009.
30. Mitnick CD, Castro KG, Harrington M, et al. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4: e292.
31. Fauci AS. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J Infect Dis 2008; 197: 1493-1498.
32. Cahn P, Perez H, Ben G, et al. Tuberculosis and HIV: a partnership against the most vulnerable. J Int Assoc Physicians AIDS Care (Chic Ill) 2003; 2: 106-123.
33. Pawinski RA, Lalloo UG. Multisectoral responses to HIV/AIDS: applying research to policy and practice. Am J Public Health 2006; 96: 1189-1191.
34. World Health Organization. Stop TB TB/HIV Working Group Strategic Plan 2006-2015. www.stoptb.org/assets/documents/global/plan/GlobalPlanFinal.pdf Date last accessed: September 13, 2010. Date last updated: 2006.
35. Lavery JV. Ethical Issues in International Biomedical Research. A Casebook. Oxford, Oxford University Press, 2007.